Abdul Mannan: A Clinical Framework for Direct Oral Anticoagulant Reversal in Acute Bleeding
Abdul Mannan, Consultant Hematologist at Betsi Cadwaladr University Health Board, shared a post on LinkedIn:
“Four TSOACs.
Four different clearance profiles.
One wrong decision at 2am in A and E.
This is for every registrar who has been in that position.
You know the drugs.
- Dabigatran.
- Rivaroxaban.
- Apixaban.
- Edoxaban.
But when someone is bleeding in front of you, knowing the name is not enough.
You need the number, the mechanism, and the right reversal agent.
In that order.
Here is what I want every trainee to have locked in:
Dabigatran is 80 percent renal. AKI doubles or triples the half-life.
It is the one TSOAC you can dialyse.
Idarucizumab 5 gram IV is your first call.
If it is not available, aPCC (FEIBA) 80 U/kg. Not 50. Not FFP. 80.
Rivaroxaban and Apixaban bleed?
Andexanet Alfa is your specific reversal agent.
But NICE TA697 (updated January 2025) restricts its use to GI tract life-threatening bleeds only.
ICH, retroperitoneal, surgical bleeds? 4F-PCC 50 U/kg.
Edoxaban is 50 percent renal.
Andexanet Alfa is not NICE-approved for it. 4F-PCC 50 U/kg. Full stop.
FFP reverses nothing here. Not Dabigatran. Not any Xa inhibitor. Put it down.
One clinical pearl that trips people up every time: Edoxaban is contraindicated in AF when CrCl goes above 95 mL/min.
Too fast clearance. Subtherapeutic levels. Paradoxical stroke risk. No other TSOAC behaves this way.
I built a free interactive dashboard covering all four drugs.
Pharmacokinetics. Lab interpretation matrix (because a normal PT does NOT rule out Apixaban).
Reversal protocols with the NICE TA697 restriction clearly flagged.
A self-assessment quiz that reshuffles every single attempt and maps your weak spots at the end.
Browser-based. Light and dark mode.
No login. No paywall.
Which part of TSOAC reversal do you find trainees get wrong most often?”
Other posts featuring Abdul Mannan on Hemostasis Today.
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association
-
Jul 2, 2026, 16:22Shinto Francis Thekkudan: Delegates Visiting our BMT and Hematology Department from Kazhakstan
-
Jul 2, 2026, 16:13William Aird: When Deciding whether an Adult Patient is Anemic, Which Do You Usually Use?
-
Jul 2, 2026, 16:08Supporting Bleeding Disorders Community and Celebrating ASPEH Milestone – WFH
-
Jul 2, 2026, 15:59Raul Santos: Why Does LDL-C Remain Elevated in Many Patients?
-
Jul 2, 2026, 15:16Tim Patel: How Regular Movement Helps Keep Blood Flowing Throughout the Day